Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 (Irinotecan, CPT-11) Oncologic Drugs Advisory Committee Review March 16, 2000 Camptosar  Pharmacia & Upjohn First-Line Therapy of Metastatic Colorectal.

Similar presentations


Presentation on theme: "1 (Irinotecan, CPT-11) Oncologic Drugs Advisory Committee Review March 16, 2000 Camptosar  Pharmacia & Upjohn First-Line Therapy of Metastatic Colorectal."— Presentation transcript:

1 1 (Irinotecan, CPT-11) Oncologic Drugs Advisory Committee Review March 16, 2000 Camptosar  Pharmacia & Upjohn First-Line Therapy of Metastatic Colorectal Cancer

2 2 Presentation Agenda  Background  2 Pivotal Phase III Controlled Clinical Trials –Improved Tumor Control –Improved Survival  Summary and Conclusions  Q&A

3 3 CPT-11 Presentation Team FunctionNameAffiliation MedicalLangdon Miller, MDP&U Paula Locker, MSP&U Gabriela Gruia, MDAventis BiostatisticalNicoletta Pirotta, MSP&U Gary Elfring, MSP&U Lucile Awad, MSAventis PharmacologyLarry Schaaf, PhDP&U InvestigatorsLeonard Saltz, MDMSKCC Jean-Yves Douillard, MD C Gauducheau Hanjochen Wilke, MDK Essen-Mitte

4 4 Background

5 5  Development of metastases: –20% of patients have metastatic disease at presentation –40% of all patients will ultimately develop metastases  Deaths due to metastatic disease: 57,000 patients  Standard first-line treatment: 5-fluorouracil (5-FU) Colorectal Cancer in 2000  US Incidence: 130,000 patients –95,000 with colon cancer –35,000 with rectal cancer American Cancer Society. Cancer Facts & Figures 2000.

6 6 Survival (median) 5-FU Therapy: With and Without LV Adding LV to 5-FU significantly improves response rate but not survival Meta-analysis Group in Cancer. J Clin Oncol. 1992;10: Meta-analysis of 9 randomized trials (N=1,381) Response Rate

7 7 5-FU Therapy: Infusional vs Bolus Infusional 5-FU significantly increases response rate but median survival remains 12 months Meta-analysis Group in Cancer. J Clin Oncol. 1998;16: Meta-analysis of 6 randomized trials (N=1,219) Response Rate Survival (median)

8 8  Novel agent with a new mechanism of action needed CPT-11 Therapy of Colorectal Cancer  CPT-11 offers: –Topoisomerase I inhibition –Consistent activity in colorectal cancer

9 9 First-Line, Single-Agent CPT-11 Therapy CPT-11 offers similar activity to that of 5-FU/LV *Conti. J Clin Oncol. 1996;14: ^Pitot. J Clin Oncol. 1997;15: Results of US phase II trials (N=72) Response Rate Survival (median)

10 10 RANDOMIZATION CPT-11: 350 mg/m 2 every 3 weeks Best Supportive Care Prior5-FU Second-Line CPT-11 Therapy (V301) Cunningham et al. Lancet. 1998; 352:

11 Months Probability Second-Line Survival (V301) p=0.0001* * log-rank test CPT-11 BSC

12 12 RANDOMIZATION CPT-11: 350 mg/m 2 every 3 weeks Infusional 5-FU-based regimen Prior5-FU Second-Line CPT-11 Therapy (V302) Rougier et al. Lancet. 1998; 352:

13 Months Probability Second-Line Survival (V302) p=0.04* * log-rank test CPT-11 Infusional 5-FU

14 14  Different mechanism of action from 5-FU Rationale for First-Line CPT-11 Combination Therapy Hypothesis: First-line combination of CPT-11 with 5-FU/LV will further improve tumor control and survival  Active as first-line, single-agent therapy  Extends survival when used as second-line therapy

15 15 *Saltz. J Clin Oncol. 1996;14:  Weekly bolus regimen (Saltz -- Study 0007) Phase I Combination Dose-Finding and Pharmacokinetic Studies  Every-2-week infusional regimen (de Gramont -- Study F106) †Ducreux. J Clin Oncol. 1999;17:  Weekly infusional regimen (AIO -- Study G101) ‡Vanhoefer. J Clin Oncol. 1999;17: Addition of CPT-11 to existing schedules of 5-FU/LV

16 16 Pivotal Phase III Trials Study Design and Conduct

17 17 Pivotal First-Line Trials Two independent, phase III, prospective, randomized, controlled, international studies CPT-11/Infusional 5-FU/LV vs Infusional 5-FU/LV Aventis Study V303 CPT-11/Bolus 5-FU/LV vs Bolus 5-FU/LV vs ( CPT-11 alone) Pharmacia & Upjohn Study 0038

18 18 Entry Criteria (0038)  Histologically proven colorectal cancer  Unresectable measurable metastases  Performance status 0, 1 or 2  No prior chemotherapy for metastatic disease  >12 months since completion of adjuvant 5-FU  No prior pelvic radiotherapy permitted  Adequate hematologic, renal, and hepatic function

19 19 Entry Criteria (V303)  Histologically proven colorectal cancer  Unresectable measurable metastases  Performance status 0, 1 or 2  No prior chemotherapy for metastatic disease  >6 months since completion of adjuvant 5-FU  Prior pelvic radiotherapy permitted  Adequate hematologic, renal, and hepatic function

20 20 Treatment (0038)  Treatment continued until tumor progression or unacceptable toxicity  Supportive care for all study arms included: –Atropine for the treatment of cholinergic symptoms –Loperamide for the treatment of late diarrhea –Antiemetics for the prophylaxis of nausea and vomiting  Second-line, post-study chemotherapy permitted

21 21 Treatment (V303)  Treatment continued until tumor progression or unacceptable toxicity  Supportive care for all study arms included: –Atropine for the treatment of cholinergic symptoms –Loperamide for the treatment of late diarrhea –Antiemetics for the prophylaxis of nausea and vomiting –Fluoroquinolone antibiotic for diarrhea in association with –Fluoroquinolone antibiotic for diarrhea in association with grade 4 neutropenia or neutropenic fever  Second-line, post-study chemotherapy permitted

22 22 Endpoints (0038)  Time to tumor progression (primary)  Tumor response rate  Survival  Safety  Quality of life (EORTC QLQ-C30)

23 23 Endpoints (V303)  Time to tumor progression  Tumor response rate (primary)  Survival  Safety  Quality of life (EORTC QLQ-C30)

24 24 Patient Evaluation (0038)  On-study assessments – Tumor measurements (q 6 weeks x 4, then q 12 weeks) – Performance status, weight, quality of life, chemistries (Day 1 of each cycle) – Adverse events, CBCs (weekly)  Follow-up –Post-study chemotherapy – Survival

25 25 Patient Evaluation (V303)  On-study assessments – Tumor measurements (q 6-7 weeks) – Performance status, weight, quality of life, chemistries (Day 1 of each cycle) – Adverse events, CBCs (weekly)  Follow-up –Post-study chemotherapy – Survival

26 26 Sample Size Calculation (0038)  Primary endpoint assumptions –40% improvement in TTP  Statistical test –  = 0.05 and 1-  = 0.85 –Unstratified log-rank  Sample size –220 patients per treatment arm

27 27 Sample Size Calculation (V303)  Primary endpoint assumptions –40% improvement in response rate  Statistical tests –  = 0.05 and 1-  = 0.80 –Unstratified chi-square  Sample size –169 patients per treatment arm

28 28 RANDOMIRANDOMIZATZATIONIONRANDOMIRANDOMIZATZATIONION Stratification:  PS (0 vs 1, 2)  Age ( 65 yr)  Time from initial diagnosis ( 6 mo)  Prior adjuvant therapy (yes vs no) CPT-11:125 mg/m 2 /wk x 4 wks, q 6 wks 5FU:500 mg/m 2 /wk x 4 wks, q 6 wks LV: 20 mg/m 2 /wk x 4 wks, q 6 wks 5FU:425 mg/m 2 /d x 5 d, q 4 wks 5FU:425 mg/m 2 /d x 5 d, q 4 wks LV: 20 mg/m 2 /d x 5 d, q 4 wks 5-FU dose intensity= 531 mg/m 2 /wk 5-FU dose intensity= 333 mg/m 2 /wk Treatment Arms (0038)

29 29 CPT-11: 80 mg/m 2 /wk x 6 wks, q 7 wks 5-FU: 2.3 gm/m 2 /wk x 6 wks, q 7 wksAIO LV:500 mg/m 2 /wk x 6 wks, q 7 wks or CPT-11: 180 mg/m 2 d1 q 2 wks 5-FU:400 IV/600 CI mg/m 2 d1, 2 q 2 wksde Gramont LV:200 mg/m 2 d1, 2 q 2 wks 5-FU: 2.6 gm/m 2 /wk x 6 wks, q 7 wksAIO LV:500 mg/m 2 /wk x 6 wks, q 7 wks or 5-FU:400 IV/600 CI mg/m 2 d1, 2 q 2 wksde Gramont LV:200 mg/m 2 d1, 2 q 2 wks RANDOMIRANDOMIZATZATIONIONRANDOMIRANDOMIZATZATIONION Treatment Arms (V303)

30 30 Study Enrollment and Follow-Up (0038)  Principal Investigator:Dr. Leonard Saltz  Number of sites:71 (Primarily North America)  Accrual period: May May 1998  Survival cut-off: December 1999 (19-month follow-up)

31 31 Study Enrollment and Follow-Up (V303)  Principal Investigator:Dr. Jean-Yves Douillard  Number of sites:83 (Primarily Europe)  Accrual period: May February 1998  Survival cut-off: October 1999 (20-month follow-up)

32 32 Pivotal Phase III Trial Results Patient Characteristics and Treatment Administration

33 33 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 Intent-to-treat population Never treated Treated on another arm As-treated population Patient Enrollment (0038)

34 34 CPT-11/5-FU/LV 5-FU/LV CPT-11/5-FU/LV 5-FU/LV [AIO][de Gramont] [AIO][de Gramont] Randomized Never treated 1 1 Full-analysis population [53] [145][44][143] Treated on other arm 0 1 As-treated population [54] [145][43][143] Patient Enrollment (V303)

35 35 CPT-11/5-FU/LV5-FU/LV CPT-11 N=231N=226N=226 Median age (yrs) [range][25-85][19-85][30-87] Gender (% of pts) M M F F Performance status (% of pts)  Demographics (0038)

36 36 CPT-11/5-FU/LV5-FU/LV N=198N=187 Median age (yrs)6261 [range][27-75][25-75] Gender (% of pts) M67 53 F3347. F3347. Performance status (% of pts)  Demographics (V303)

37 37 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 N=231N=226N=226 Primary site (% of pts) Colon Rectum Number of involved organ sites (% of pts) > Liver involvement (% of pts) Disease Characteristics (0038)

38 38 CPT-11/5-FU/LV 5-FU/LV CPT-11/5-FU/LV 5-FU/LV N=198N=187 Primary site (% of pts) Colon5565 Rectum4536 Number of involved organ sites (% of pts) >23837 Liver involvement (% of pts)7780 Disease Characteristics (V303)

39 39 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 N=231N=226N=226 Median time from initial diagnosis (mo) [range][ ][ ][ ] Prior adjuvant 5-FU (% of pts) Pelvic radiotherapy 211 (% of pts) Disease History (0038)

40 40 CPT-11/5-FU/LV 5-FU/LV CPT-11/5-FU/LV 5-FU/LV N=198N=187 Median time from initial diagnosis (mo) [range][0.1-88][ ] Prior adjuvant 5-FU2624 (% of pts) Radiotherapy2016 (% of pts) Disease History (V303)

41 41 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 N=231N=226N=226 Abnormal baseline value (% of pts) Hgb <11 g/dL WBC  8x10 9 /L LDH >ULN Bilirubin >ULN CEA  100 ng/mL Baseline Laboratory Abnormalities (0038) *ULN = upper limit of normal

42 42 CPT-11/5-FU/LV 5-FU/LV CPT-11/5-FU/LV 5-FU/LV N=198N=187 Abnormal baseline value (% of pts) Hgb <11 g/dL1621 WBC  8x10 9 /L4738 LDH >ULN4044 Bilirubin >ULN 7 7 CEA  100 ng/mL3532 Baseline Laboratory Abnormalities (V303) *ULN = upper limit of normal

43 43 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 N=225N=219N=223 Median duration (mo) [range][0.3-33][0.4-22][0.2-18]. Median dose intensity (mg/m 2 /wk) [Median relative dose intensity*] 5-FU236 [0.71]457 [0.86]-- CPT [0.72]--62 [0.75] Treatment Administration (0038) *Ratio of actual dose intensity relative to planned dose intensity

44 44 CPT-11/5-FU/LV 5FU/LV CPT-11/5-FU/LV 5FU/LV N=199 N=186 N=199 N=186 AIOde Gramont AIOde Gramont N=54N=145N=43N=143 Median duration (mo) Median duration (mo) [range][ ] [ ] [ ][ ] [range][ ] [ ] [ ][ ] Median relative dose intensity * CPT FU Treatment Administration (V303) *Ratio of actual dose intensity relative to planned dose intensity

45 45 Pivotal Phase III Trial Results Efficacy and Safety

46 46 CPT-11/5-FU/LV5-FU/LVCPT-11 N=(231,198)N=(226,187)N=226 Study %21%18% Study V303 35% 22% Confirmed Response Rates (0038,V303) Responses confirmed  4 weeks after initial objective response *Chi-square test p<0.005* p<0.0001*

47 47 CPT-11/5-FU/LV5-FU/LVCPT-11 N=(231,198)N=(226,187)N=226 Median (0038) 7.0 mo4.3 mo4.2 mo Median (V303) 6.7 mo 4.4 mo *Log-rank test Time to Tumor Progression (0038,V303) p=0.004* p<0.001*

48 Months Probability CPT-11/5-FU/LV (N=231) 5-FU/LV (N=226) * log-rank test p=0.004* Time to Tumor Progression (0038)

49 Months Probability CPT-11/5-FU/LV (N=198) 5-FU/LV (N=187) Time to Tumor Progression (V303) p<0.001* * log-rank test

50 50 Hazard Ratio Factor Value[95% CI]p-value Factor Value[95% CI]p-value LDH  UNL vs >UNL [ ] Organ sites1 vs  2 sites [0.50–0.80] PS0 vs  [0.59–0.93] Bilirubin  UNL vs >UNL [0.35–0.89] Hemoglobin< 11 vs  11 g/dL [0.58–0.95] Age  65 vs <65 years [0.63–0.98] TreatmentCPT-11/5-FU/LV vs 5-FU/LV [0.51–0.79] vs 5-FU/LV [0.51–0.79] *ULN=upper limit of normal Cox Regression Analysis: TTP (0038)

51 51 Hazard Ratio Factor Value[95% CI]p-value Factor Value[95% CI]p-value Organ sites1 vs  2 sites [0.57–0.94] LDH  UNL vs >UNL [ ] TreatmentCPT-11/5-FU/LV vs 5-FU/LV [0.46–0.76] vs 5-FU/LV [0.46–0.76] Cox Regression Analysis: TTP (V303)

52 52 CPT-11/5-FU/LV5-FU/LVCPT-11 N=(231,198)N=(226,187)N=226 Median (0038)14.8 mo12.6 mo12.0 mo Median (V303)17.4 mo 14.1 mo Survival (0038,V303) *Log-rank test p=0.042* p=0.032*

53 Months CPT-11/5-FU/LV (N=231) 5-FU/LV (N=226) Survival (0038) p=0.042* Probability * log-rank test

54 54 Survival (V303) Months Probability CPT-11/5-FU/LV (N=198) 5-FU/LV (N=187) p=0.032* * log-rank test

55 55 Hazard Ratio Factor Value[95% CI]p-value Factor Value[95% CI]p-value LDH  UNL vs >UNL [ ] PS0 vs  [0.45–0.71] WBC <8 vs  8 x 10 9 /L [0.51–0.80] Organ sites1 vs  2 sites [0.54–0.84] Bilirubin  UNL vs >UNL [0.35–0.86] TreatmentCPT-11/5-FU/LV vs 5-FU/LV [0.64–0.99] vs 5-FU/LV [0.64–0.99] Cox Regression Analysis: Survival (0038)

56 56 Hazard Ratio FactorValue[95% CI]p-value LDH  UNL vs >UNL [ ] PS0 vs  [0.41–0.67] Time from  1 vs < 1 mo Metastatic Dx [ ] Organ sites1 vs  2 sites [0.57–0.94] TreatmentCPT-11/5-FU/LV [vs 5-FU/LV] [0.61–0.98] [vs 5-FU/LV] [0.61–0.98] Cox Regression Analysis: Survival (V303)

57 57 CPT-11/5-FU/LV5-FU/LV CPT-11 N=205N=203N=195 Patients with any 52%70%79% post-study therapy CPT-11-based 1%38% 3% CPT-11+5-FU-based13%18% 9% 5-FU-based30%10% 64% Other therapy 8% 4% 3% Patients not treated48%30%21% Post-Study Therapy (0038) 56% 

58 58 CPT-11/5-FU/LV5-FU/LV N=167N=171 Patients with any 49%65% post-study therapy CPT-11-based 2%28% CPT-11+5-FU-based 4% 6% 5-FU-based32%21% Other therapy11%10% Patients not treated51%35% Post-Study Therapy (V303) 34% 

59 59 CPT-11/5-FU/LV 5-FU/LV CPT-11 CPT-11/5-FU/LV 5-FU/LV CPT-11 Event (% of pts) N=225N=219N=223 Diarrhea, grade 3/ Grade Grade Vomiting, grade 3/ Mucositis, grade 3/ Neutropenia, grade Neutropenic fever Neutropenic infection Discontinuations Drug-related deaths Adverse Events (0038)

60 60 CPT-11/5-FU/LV 5-FU/LV CPT-11/5-FU/LV 5-FU/LV Event (% of pts) N=199N=186 Diarrhea, grade 3/42311 Grade Grade Vomiting, grade 3/4 6 3 Mucositis, grade 3/4 3 3 Neutropenia, grade Neutropenic fever 5 1 Neutropenic infection 2 0 Discontinuations 9 3 Drug-related deaths Adverse Events (V303)

61 61 Quality of Life Pivotal Phase III Trial Results  Study 0038 primary endpoints –Global health status –Role functioning –Pain  Study V303 primary endpoint –Global health status

62 62 Global Health Status Subscale Weeks Better Worse Mean Change (  se) EORTC QLQ-C30 Quality of Life (0038) CPT-11/5-FU/LV 5-FU/LV

63 EORTC QLQ-C30 Quality of Life (0038) Weeks Better Worse Mean Change (  se) Role Functioning Subscale CPT-11/5-FU/LV 5-FU/LV

64 Weeks Worse Better Mean Change (  se) Pain Subscale EORTC QLQ-C30 Quality of Life (0038) CPT-11/5-FU/LV 5-FU/LV

65 65 Global Health Status Subscale Weeks Better Worse Mean Change (  se) EORTC QLQ-C30 Quality of Life (V303) CPT-11/5-FU/LV 5-FU/LV

66 66 Summary and Conclusions Two independent, phase III, prospective, randomized, controlled, multinational studies

67 67  Significantly lengthens time to tumor progression Efficacy Summary  Significantly improves response rate First-line combination CPT-11/5-FU/LV  Significantly prolongs survival

68 68 Safety Summary  Predictable and manageable side effect profile First-line combination CPT-11/5-FU/LV  Similar incidence of grade 4 diarrhea relative to 5-FU/LV  Low rates of grade 3/4 vomiting, mucositis, neutropenia, and febrile neutropenia

69 69 Quality of Life Summary  Prolongs life without compromising quality of life First-line combination CPT-11/5-FU/LV

70 70Conclusion  CPT-11-based combination therapy sets  CPT-11-based combination therapy sets a new standard in the first-line treatment of metastatic colorectal cancer

71 71 Proposed New Indication   CPT-11 should be indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum   Recommended CPT-11/5-FU/LV regimens: – –Saltz – –de Gramont

72 72 Q & A


Download ppt "1 (Irinotecan, CPT-11) Oncologic Drugs Advisory Committee Review March 16, 2000 Camptosar  Pharmacia & Upjohn First-Line Therapy of Metastatic Colorectal."

Similar presentations


Ads by Google